WARPTECHNEWS · LAB
HomeAIBusinessTechArchive
WARPTECH LAB NEWS

Warptech Lab News aggrega le notizie più rilevanti da oltre 700 fonti internazionali, con classificazione AI, TL;DR sintetici e timeline cluster su singole storie.

Navigazione

  • Home
  • Archivio
  • Editor's Brief
  • Cerca
  • Il tuo account
  • Newsletter tech/AI

Informazioni legali

  • Privacy Policy
  • Termini di servizio
  • Cookie Policy

© 2026 Sparktech S.R.L. — Tutti i diritti riservati. Sito gestito e manutenuto da Sparktech S.R.L.

Sede legale: Corso Libertà 55, 13100 Vercelli (VC), Italia · P.IVA / C.F. 02835910023 · Contatti: admin@warptechlab.com

Home
Storia in 5 fonti

FDA approves Zaynich for complicated UTIs

The FDA approved Zaynich as an intravenous treatment for complicated urinary tract infections, including pyelonephritis, in adults, according to a press release from the antibiotic’s manufacturer, Wockhardt.“The threat of drug-resistant infections is an escalating crisis, leaving clinicians with fewer tools to treat patients facing these aggressive pathogens. The FDA approval of

Raccontata daeconomictimes.indiatimes.comthehindubusinessline.commorningstar.comtimesofindia.indiatimes.comhealio.com

Confronto fonti

5 prospettive sulla stessa storia
AI · summaries
healio.comStai leggendo21 h fa

FDA approves Zaynich for complicated UTIs

The FDA approved Zaynich as an intravenous treatment for complicated urinary tract infections, including pyelonephritis, in adults, according to a press release from the antibiotic’s manufacturer, Wockhardt.“The threat…

originale
morningstar.com1 g fa

Wockhardt Receives U.S. FDA Approval for ZAYNICH™ (cefepime and zidebactam), a Novel Intravenous Antibiotic…

Wockhardt Receives U.S. FDA Approval for ZAYNICH™ (cefepime and zidebactam), a Novel Intravenous Antibiotic for the Treatment of Adult Patients with Complicated Urinary Tract Infection Including Pyelonephritis

Leggi questa versione → originale
economictimes.indiatimes.com1 g fa

FDA approval puts Wockhardt’s Zaynich in $9 billion antibiotics market

Wockhardts newly approved antibiotic Zaynich has the potential to transform the treatment of drug-resistant infections, according to Mahesh Patel, the scientist behind the drug. Approved by the US FDA for complicated…

Leggi questa versione → originale
thehindubusinessline.com1 g fa

Wockhardt marks research milestone with USFDA approval for novel antibiotic Zaynich

Wockhardt received FDA approval for Zaynich (cefepime + zidebactam), the first New Chemical Entity fully developed by an Indian pharma company to clear FDA, with Phase 3 data showing 89% efficacy vs 68.4% for meropenem in cUTI. The approval targets antimicrobial resistance — a growing clinical and procurement priority — and signals that non-Western pharma R&D pipelines are producing first-in-class assets with credible Phase 3 validation.

Leggi questa versione → originale
timesofindia.indiatimes.com1 g fa

'USFDA nod for Zaynich a major boost'

NEW DELIH: The US Food and Drug Administration's approval of Wockhardt's Zaynich, a first-in-class 'breakthrough antibiotic' for severe drug-resistant infections, opens up a significant global market opportunity, the…

Leggi questa versione → originale

Timeline cronologica

  1. sabato 30 maggio 2026·economictimes.indiatimes.com

    Wockhardt secures US FDA approval for antibiotic Zaynich

    Wockhardt's novel antibiotic, Zaynich (cefepime and zidebactam), has received US FDA approval for complicated urinary tract infections. This breakthrough drug targets superbugs…

  2. lunedì 1 giugno 2026·economictimes.indiatimes.com

    FDA approval puts Wockhardt’s Zaynich in $9 billion antibiotics market

    Wockhardts newly approved antibiotic Zaynich has the potential to transform the treatment of drug-resistant infections, according to Mahesh Patel, the scientist behind the drug.…

  3. lunedì 1 giugno 2026·economictimes.indiatimes.com

    Wockhardt shares in focus after FDA approval for antibiotic targeting drug-resistant infections. Check details

    Wockhardt will be in focus after the US FDA approved ZAYNICH, a novel intravenous antibiotic combining cefepime and zidebactam for complicated urinary tract infections. The drug…

  4. lunedì 1 giugno 2026·thehindubusinessline.com

    Wockhardt marks research milestone with USFDA approval for novel antibiotic Zaynich

    Zaynich (cefepime and zidebactam) is an injectable antibiotic comprising cefepime, a cephalosporin antibacterial drug and zidebactam, a non-β-lactam antibacterial and β-lactamase…

  5. lunedì 1 giugno 2026·morningstar.com

    Wockhardt Receives U.S. FDA Approval for ZAYNICH™ (cefepime and zidebactam), a Novel Intravenous Antibiotic for the Treatment of Adult…

    Wockhardt Receives U.S. FDA Approval for ZAYNICH™ (cefepime and zidebactam), a Novel Intravenous Antibiotic for the Treatment of Adult Patients with Complicated Urinary Tract…

  6. lunedì 1 giugno 2026·timesofindia.indiatimes.com

    'USFDA nod for Zaynich a major boost'

    NEW DELIH: The US Food and Drug Administration's approval of Wockhardt's Zaynich, a first-in-class 'breakthrough antibiotic' for severe drug-resistant infections, opens up a…

  7. martedì 2 giugno 2026·healio.com

    FDA approves Zaynich for complicated UTIs

    The FDA approved Zaynich as an intravenous treatment for complicated urinary tract infections, including pyelonephritis, in adults, according to a press release from the…